Latest News
Conference Coverage
CLL drug combinations induce MRD negativity
ATLANTA – The potential of two- and three-drug combinations to induce MRD-negative responses in CLL patients was demonstrated in multiple studies...
Conference Coverage
VIDEO: CTCs may identify asymptomatic late breast cancer recurrences
Circulating tumor cells may play a role in identifying late breast cancer recurrences in otherwise asymptomatic women
Video
MACRA Monday: BMI screening and follow-up
Calculating one patient’s BMI and developing a follow-up plan could help you avoid a 4% MIPS penalty.
Conference Coverage
MAVORIC: Mogamulizumab tops vorinostat in pretreated CTCL
ATLANTA – Mogamulizumab topped vorinostat in terms of overall response to treatment and on several quality of life scales
Conference Coverage
CLARITY: Ibrutinib/venetoclax combo results look promising for relapsed/refractory CLL
ATLANTA – Ibrutinib/venetoclax is well tolerated and shows promise for relapsed/refractory CLL, according to early CLARITY feasibility trial...
Conference Coverage
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas
ATLANTA – Updated results in 108 patients with refractory B cell lymphomas showed an ORR of 82%, including 58% complete responses, after a median...
Conference Coverage
Guideline preview: ASH to recommend against VTE prophylaxis for lower-risk cancer patients
ATLANTA – ASH attendees got a preview of forthcoming recommendations on prevention and treatment of VTE in patients with cancer.
Conference Coverage
Avapritinib yields high response rate in patients with systemic mastocytosis
ATLANTA – Avapritinib was well tolerated in the phase 1 trial, and demonstrated encouraging preliminary activity.
Conference Coverage
Intrabone gene therapy shows promise in beta-thalassemia
ATLANTA – Intrabone gene therapy could offer long-term hope for patients with beta-thalassemia who cannot be treated by allogeneic HSCT.
Conference Coverage
Gene therapy normalized or near-normalized factor VIII in hemophilia A
ATLANTA – Gene therapy is “holy grail” for managing hemophilia – a single-gene disorder with a clear relationship between clotting factor level...
Conference Coverage
Gene therapy regimen for XSCID shows rapid results in newly diagnosed infants
ATLANTA – The regimen combines a modified lentiviral vector with reduced exposure busulfan conditioning.